MDxHealth Enters Agreement with University Hospital of Bonn for Use of the Epigenetic MGMT test in Phase III Brain Cancer

IRVINE, Calif., & LIEGE, Belgium--(BUSINESS WIRE)-- Regulatory News:

MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, announced today that it has entered into a companion diagnostic agreement with Prof. Dr. Ulrich Herrlinger of the Division of Clinical Neuro-oncology of the University Hospital of Bonn (Germany) to provide MGMT epigenetic testing.

MDxHealth’s epigenetic MGMT test (PredictMDxTM for Glioblastoma) will be used to select patients to enroll in a randomized, multicenter phase III clinical study examining the addition of lomustine (also known as CCNU) to the current therapy of temozolomide/radiotherapy in MGMT methylated, newly diagnosed glioblastoma multiforme (GBM) patients, a severe form of brain cancer. The study, called CeTeG, will start recruiting patients this month and will last for approximately 2 years. Financial terms of the deal were not disclosed.

About PredictMDxTM for Glioblastoma:

PredictMDx for Glioblastoma, MDxHealth's most advanced epigenetic assay is designed to identify newly diagnosed GBM patients most likely to benefit from treatment with alkylating agents. The test assesses the methylation status of the MGMT gene, which assists clinicians in treatment decision making for patients requiring chemotherapy. This patented methylation-specific PCR test is a proven companion diagnostic for new brain cancer drug developers since they can more readily target their new compounds to the patients who usually do not respond to the traditional alkylating agent drug regimen.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on proprietary gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. More information can be found on the Company website: or on twitter at the following address:

MDxHealth to present at the Biotech Showcase in San Francisco, January 9-11, 2012

MDxHealth will present at the Biotech Showcase in San Francisco in January. Dr. Jan Groen, CEO, will make a formal presentation on the Company at the Parc 55 Wyndham San Francisco – Union Square.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation


Dr. Jan Groen, CEO
[email protected]
Halsin Partners
Mike Sinclair
[email protected]

KEYWORDS:   United States  Belgium  Europe  North America  California  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Research  Science